Clinical trial
High-dose Cephalexin for Cellulitis (HI-DOCC)
NCT05852262 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- High-dose Cephalexin for Cellulitis (HI-DOCC)
- Lead sponsor
- Ottawa Hospital Research Institute
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- August 30, 2023
- Completion date
- April 5, 2026
- Enrollment
- 454 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.